Company intelligence / Profile preview
OcuTerra Therapeutics
Boston, Massachusetts, United Statesocuterratx.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
OcuTerra's lead candidate nesvategrast (OTT166 5%) completed Phase 2 clinical trials (DR:EAM study) in March 2024. The drug met its primary safety endpoint but failed to meet primary and secondary efficacy endpoints for treating diabetic retinopathy. The company is reviewing the full dataset to evaluate the future of the program.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on OcuTerra Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OcuTerra Therapeutics.